Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 March 2006, Vol. 107, No. 5, pp. 1791-1799.
Prepublished online as a Blood First Edition Paper on October 27, 2005; DOI 10.1182/blood-2005-04-1466.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-04-1466v1
107/5/1791    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schnittger, S.
Right arrow Articles by Schoch, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schnittger, S.
Right arrow Articles by Schoch, C.
Related Collections
Right arrow Oncogenes and Tumor Suppressors
Right arrow Clinical Trials and Observations
Right arrow Neoplasia
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CLINICAL TRIALS AND OBSERVATIONS

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival

Susanne Schnittger, Tobias M. Kohl, Torsten Haferlach, Wolfgang Kern, Wolfgang Hiddemann, Karsten Spiekermann, and Claudia Schoch

From the Laboratory of Leukemia Diagnostics and the Clinical Cooperative group "Leukemia," Department of Medicine III, University Hospital Grosshadern, Ludwig-Maximilians University, Munich; and the GSF-National Research Center for Environment and Health, Munich, Germany.

Mutations in codon D816 of the KIT gene represent a recurrent genetic alteration in acute myeloid leukemia (AML). To clarify the biologic implication of activation loop mutations of the KIT gene, 1940 randomly selected AML patients were analyzed. In total, 33 (1.7%) of 1940 patients were positive for D816 mutations. Of these 33 patients, 8 (24.2%) had a t(8;21), which was significantly higher compared with the subgroup without D816 mutations. Analyses of genetic subgroups showed that KIT-D816 mutations were associated with t(8;21)/AML1-ETO and other rare AML1 translocations. In contrast, other activating mutations like FLT3 and NRAS mutations were very rarely detected in AML1-rearranged leukemia. KIT mutations had an independent negative impact on overall (median 304 vs 1836 days; P = .006) and event-free survival (median 244 vs 744 days; P = .003) in patients with t(8;21) but not in patients with a normal karyotype. The KIT-D816V receptor expressed in Ba/F3 cells was resistant to growth inhibition by the selective PTK inhibitors imatinib and SU5614 but fully sensitive to PKC412. Our findings clearly indicate that activating mutations of receptor tyrosine kinases are associated with distinct genetic subtypes in AML. The KIT-D816 mutations confer a poor prognosis to AML1-ETO-positive AML and should therefore be included in the diagnostic workup. Patients with KIT-D816-positive/AML1-ETO-positive AML might benefit from early intensification of treatment or combination of conventional chemotherapy with KIT PTK inhibitors.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
haematolHome page
K. Dohner and H. Dohner
Molecular characterization of acute myeloid leukemia
Haematologica, July 1, 2008; 93(7): 976 - 982.
[Full Text] [PDF]


Home page
haematolHome page
A. Pulsoni, S. Iacobelli, M. Bernardi, M. Borgia, A. Camera, N. Cantore, F. Di Raimondo, P. Fazi, F. Ferrara, F. Leoni, et al.
M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience
Haematologica, July 1, 2008; 93(7): 1025 - 1032.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
F. Lo-Coco, A. Cuneo, F. Pane, D. Cilloni, D. Diverio, M. Mancini, N. Testoni, A. Bardi, B. Izzo, N. Bolli, et al.
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia
Haematologica, July 1, 2008; 93(7): 1017 - 1024.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Hu, H. Niu, P. Minkin, S. Orwick, A. Shimada, H. Inaba, G. V.H. Dahl, J. Rubnitz, and S. D. Baker
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
Mol. Cancer Ther., May 1, 2008; 7(5): 1110 - 1120.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. H. Tomasson, Z. Xiang, R. Walgren, Y. Zhao, Y. Kasai, T. Miner, R. E. Ries, O. Lubman, D. H. Fremont, M. D. McLellan, et al.
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia
Blood, May 1, 2008; 111(9): 4797 - 4808.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. S. Braun and K. Shannon
Targeting Ras in Myeloid Leukemias
Clin. Cancer Res., April 15, 2008; 14(8): 2249 - 2252.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
R. M. Stone
Genetically Defined Prognostic Factors and Novel Therapeutics for AML
ASCO Educational Book, January 1, 2008; 2008(1): 280 - 284.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. Munugalavadla, E. C. Sims, J. Borneo, R. J. Chan, and R. Kapur
Genetic and pharmacologic evidence implicating the p85{alpha}, but not p85{beta}, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis
Blood, September 1, 2007; 110(5): 1612 - 1620.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. Dicker, C. Haferlach, W. Kern, T. Haferlach, and S. Schnittger
Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia
Blood, August 15, 2007; 110(4): 1308 - 1316.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
U. Bacher, T. Haferlach, W. Kern, C. Haferlach, and S. Schnittger
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia
Haematologica, June 1, 2007; 92(6): 744 - 752.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. Meshinchi and R. J. Arceci
Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia
Oncologist, March 1, 2007; 12(3): 341 - 355.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
H. Dohner
Implication of the Molecular Characterization of Acute Myeloid Leukemia
Hematology, January 1, 2007; 2007(1): 412 - 419.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
C. Akin
Molecular Diagnosis of Mast Cell Disorders: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology
J. Mol. Diagn., September 1, 2006; 8(4): 412 - 419.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Paschka, G. Marcucci, A. S. Ruppert, K. Mrozek, H. Chen, R. A. Kittles, T. Vukosavljevic, D. Perrotti, J. W. Vardiman, A. J. Carroll, et al.
Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study
J. Clin. Oncol., August 20, 2006; 24(24): 3904 - 3911.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
U. Bacher, T. Haferlach, C. Schoch, W. Kern, and S. Schnittger
Implications of NRAS mutations in AML: a study of 2502 patients
Blood, May 15, 2006; 107(10): 3847 - 3853.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
K. Mrozek and C. D. Bloomfield
Chromosome Aberrations, Gene Mutations and Expression Changes, and Prognosis in Adult Acute Myeloid Leukemia
Hematology, January 1, 2006; 2006(1): 169 - 177.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020